Amarin Corporation plc AMRN

AMRN Company Overview

Amarin Corporation plc is a biopharmaceutical company focused on the development and commercialization of prescription therapies for cardiovascular disease. The company operates within the pharmaceutical and biotechnology industries, with its business centered on lipid science and cardiovascular risk reduction. Amarin’s primary product and revenue driver is VASCEPA, a prescription omega-3 fatty acid–based therapy approved to reduce cardiovascular risk in certain patient populations.

The company’s key customer segments include cardiologists, primary care physicians, hospitals, and healthcare systems, with end users being patients at elevated risk of cardiovascular events. Amarin’s strategic positioning is based on clinical outcomes data demonstrating cardiovascular risk reduction beyond lipid lowering, which differentiates VASCEPA from dietary supplements and generic omega-3 products. Amarin was founded in 1993 and evolved from a development-stage biotechnology firm into a commercial-stage pharmaceutical company following U.S. regulatory approval and subsequent international market expansion of VASCEPA.